AGIOS PHARMACEUTICALS, INC. (AGIO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, AGIOS PHARMACEUTICALS, INC. reported revenue of $54.03M, up 48.0% from the prior year. The company ran a net loss, with a net margin of -764.0%. It held $1.30B in total assets against $104.11M in total liabilities.
Key ratios (FY2025)
-873.9%
Operating margin
-764.0%
Net margin
-34.6%
Return on equity
+48.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.03M | $36.50M | $26.82M | $14.24M | $0 | $0 | $117.91M | $94.39M | $43.01M | $69.89M |
| Cost of Revenue | $6.34M | $4.17M | $2.88M | $1.70M | $0 | $0 | $1.32M | $1.40M | $0 | $0 |
| Operating Income | -$472.13M | -$425.74M | -$391.49M | -$389.05M | -$378.42M | -$335.92M | -$316.27M | -$362.48M | -$320.79M | -$200.99M |
| Net Income | -$412.78M | $673.73M | -$352.09M | -$231.80M | $1.60B | -$327.37M | -$411.47M | -$346.03M | -$314.67M | -$198.47M |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | — | — | — |
| Total Assets | $1.30B | $1.66B | $937.12M | $1.24B | $1.44B | $852.95M | $890.74M | $858.46M | $614.40M | $619.09M |
| Total Liabilities | $104.11M | $122.24M | $126.10M | $137.90M | $145.76M | $453.45M | $250.21M | $170.92M | $238.89M | $260.50M |
| Shareholders' Equity | $1.19B | $1.54B | $811.02M | $1.10B | $1.29B | $399.50M | $640.53M | $687.54M | $375.50M | $358.59M |
| Cash & Equivalents | $89.13M | $76.25M | $88.20M | $139.26M | $203.13M | $127.44M | $80.93M | $70.50M | $102.72M | $160.75M |
| Operating Cash Flow | -$372.98M | -$389.84M | -$296.06M | -$309.48M | -$407.32M | -$290.76M | -$370.62M | -$304.42M | -$285.23M | $38.56M |
| Capital Expenditures | $4.32M | $1.69M | $999.0K | $4.88M | $5.74M | $14.11M | $12.03M | $6.99M | $4.63M | $9.91M |
| Shares Outstanding | 58.45M | 57.16M | 55.95M | 55.04M | 54.33M | 69.29M | 68.40M | 58.22M | 48.83M | 42.22M |